Method and composition for treatment of inflammatory conditions
Methods of treating inflammation of the gastrointestinal tract and/or systemic or local inflammation by administering a steroid anti-inflammatory or a non-steroid anti-inflammatory drug in conjunction with polyunsaturated fatty acids or their derivatives and optionally also a pharmacologically active antioxidant and compositions for practicing these methods are described.
1 . A pharmaceutical composition for the treatment of an inflammatory condition in a mammal consisting essentially of budesonide or a prodrug or derivative thereof, in a highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acids, or derivatives thereof, optionally also including a pharmaceutically acceptable carrier, a diluent, a viscosity modifier, a stabilizer, an erodable or swallowable matrix, and a penetration enhancer.
2 . The pharmaceutical composition of claim 1 , wherein the antioxidant is a tocopherol.
3 . The pharmaceutical composition of claim 2 , wherein the tocopherol is a mixture of alpha- and gamma-isomers.
4 . The pharmaceutical composition of claim 1 , where the omega-3 and/or omega-6 and omega-9 polyunsaturated fatty acid, or a prodrug or a derivative thereof, are in the form of a tri-, di, or mono-glyceride, methyl/ethyl ester, free fatty acid, or other bio-available form.
5 . The pharmaceutical composition of claim 4 , wherein the budesonide, or a prodrug or derivative thereof is fully solubilized.
6 . The pharmaceutical composition of claim 4 , wherein the budesonide, or a prodrug or derivative thereof is fully suspended.
7 . The pharmaceutical composition of claim 4 , wherein the budesonide, or a prodrug or derivative thereof is partially suspended.
8 . The pharmaceutical composition of claim 1 , wherein the composition provides from 0.1 to 30 grams per day of omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acids, or derivatives thereof.
9 . An orally or enterally administrable composition for the treatment of an inflammatory conditions of the gastrointestinal tract, consisting essentially of an effective amount of budesonide, or a prodrug or derivative thereof, highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acid; and an antioxidant, optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, and an erodable or swallowable matrix.
10 . An orally administrable composition for the treatment of a systemic or local inflammatory condition consisting essentially of an effective amount of budesonide, or a prodrug or derivative thereof, highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acid, and an antioxidant, optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, an erodable or swallowable matrices, and/or a penetration enhancer.
11 . The pharmaceutical composition of claim 9 , wherein the composition is encapsulated and enteric-coated for release and/or delivery of drug of about 55% into the proximal small bowel.
12 . The pharmaceutical composition of claim 9 , wherein the composition is encapsulated and enteric-coated for release and/or delivery of drug of about 25% into the proximal small bowel.
13 . The pharmaceutical composition of claim 9 , wherein the composition is encapsulated and enteric-coated for release and/or delivery of drug of about 25% into the ascending and transverse colon.
14 . A topically administrable composition for the treatment of a systemic or local inflammatory condition consisting essentially of an effective amounts of budesonide, or a prodrug or derivative thereof; highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acid; and an antioxidant; optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, an erodable matrix, and/or a penetration enhancer.
15 . A pharmaceutical composition for the treatment of an inflammatory condition in a mammal, the composition consisting essentially of a steroid or non-steroidal anti-inflammatory drug; highly purified omega-3 and/or omega-6 and/or omega-9-polyunsaturated acid or a derivative thereof, and optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, an erodable and swallowable matrix, and/or a penetration enhancer.
16 . A pharmaceutical composition for the treatment of an inflammatory condition in a mammal consisting of budesonide or a prodrug or derivative thereof, in a highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acids, or derivatives thereof, optionally also including a pharmaceutically acceptable carrier, a diluent, a viscosity modifier, a stabilizer, an erodable or swallowable matrix, and a penetration enhancer.
17 . An orally or enterally administrable composition for the treatment of an inflammatory conditions of the gastrointestinal tract, consisting of an effective amount of budesonide, or a prodrug or derivative thereof, highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acid; and an antioxidant, optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, and an erodable or swallowable matrix.
18 . An orally administrable composition for the treatment of a systemic or local inflammatory condition consisting of an effective amount of budesonide, or a prodrug or derivative thereof, highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acid, and an antioxidant, optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, an erodable or swallowable matrices, and/or a penetration enhancer.
19 . A topically administrable composition for the treatment of a systemic or local inflammatory condition consisting of an effective amount of budesonide, or a prodrug or derivative thereof, highly purified omega-3 and/or omega-6 and/or omega-9 polyunsaturated fatty acid; and an antioxidant; optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, an erodable matrix, and/or a penetration enhancer.
20 . A pharmaceutical composition for the treatment of an inflammatory condition in a mammal, the composition consisting of a steroid or non-steroidal anti-inflammatory drug; highly purified omega-3 and/or omega-6 and/or omega-9-polyunsaturated acid or a derivative thereof, and optionally including a pharmaceutically acceptable carrier, a diluent, a viscosity-modifier, a stabilizer, an erodable and swallowable matrix, and/or a penetration enhancer.